$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[국내논문] 사용금기 약물에 대한 의약품안전사용서비스의 효과에 대한 체계적 문헌고찰
The Effects after Implementing a Drug Utilization Review System on Contraindicated Drug use: A Systematic Review 원문보기

한국임상약학회지 = Korean journal of clinical pharmacy, v.29 no.1, 2019년, pp.9 - 17  

이희영 (가천대학교 약학대학) ,  최혜숙 (가천대학교 약학대학) ,  지은희 (가천대학교 약학대학)

Abstract ▼ AI-Helper 아이콘AI-Helper

Objective: The objective of the present study was to evaluate the effects of implementing a systematic Drug Utilization Review (DUR) system on contraindicated drug use and pharmaceutical expenditures in Korea. Methods: A literature search was conducted using search engines such as PubMed, EMBASE, ND...

주제어

#Drug utilization review system   #contraindicated drugs   #pharmaceutical expenditure   #systematic review   #Korea  

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

제안 방법

  • These three studies showed the effects of implementing DUR system on the trend of pharmaceutical expenditures without indicating specific types of medications they analyzed.

대상 데이터

  • Additionally, 92 eligible articles were chosen from NDSL and RISS. After full-text review, 67 articles were selected. Fifty-six studies were excluded, and 11 articles were included in the present systematic review (Fig.
  • After full-text review, 67 articles were selected. Fifty-six studies were excluded, and 11 articles were included in the present systematic review (Fig. 1). We did not include any article following the manual search.
본문요약 정보가 도움이 되었나요?

참고문헌 (36)

  1. Hennessy S, Soumerai SB, Lipton HL, Strom BL. Drug utilization review. Pharmacoepidemiology 2006;439-53. 

  2. Fulda TR, Lyles A, Pugh MC, Christensen DB. Current status of prospective drug utilization review. J Manag Care Pharm 2004;10:433-41. 

    상세보기

  3. Youn SH, Lee SS, Kim S, et al. Drug utilization review of mupirocin ointment in a Korean university-affiliated hospital. Korean J Intern Med 2015;30:515-20. 

    상세보기

  4. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005;28:67-80. 

    상세보기

  5. Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. Int J Legal Med 2011;125:803-15. 

  6. Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study. Nephrol Dial Transplant 2011;26:2852-9. 

    상세보기

  7. Heaton A. High frequency of itraconazole prescriptions with potentially interacting medications in a large health care plan. J Manag Care Pharm 2002;8:199-203. 

    상세보기

  8. Jones JK, Fife D, Curkendall S, Goehring E, Jr., Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001;286:1607-9. 

    상세보기

  9. Lyles A, Zuckerman IH, DeSipio SM, Fulda T. When Warnings Are Not Enough: Primary Prevention Through Drug Use Review: To avoid adverse drug interactions, clinical data should follow the patient in the same way that financial data do. Health Aff (Millwood) 1998;17:175-83. 

  10. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284:3036-9. 

    상세보기

  11. Wagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369-86. 

    상세보기

  12. Moja L, Kwag KH, Lytras T, et al. Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. Am J Public Health 2014;104:e12-e22. 

    상세보기

  13. Song SO, Jung CH, Song YD, et al. Background and data configuration process of a nationwide population-based study using the korean national health insurance system. Diabetes Metab J 2014;38:395-403. 

    상세보기

  14. Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions-Systematic review and methodological considerations. Br J Clin Pharmacol 2018;84:419-33. 

    상세보기

  15. Vander Stichele R, Elseviers M, Ferech M, Blot S, Goossens H. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol 2004;58:419-28. 

    상세보기

  16. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87. 

  17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. 

    상세보기

  18. Heo JH, Suh DC, Kim S, Lee EK. Evaluation of the pilot program on the real-time drug utilization review system in South Korea. Int J Med Inform 2013;82:987-95. 

  19. Lee SO, Je NK, Kim D-S, Hwang IO, Cheun BO. Tiering 'Drug Combinations to Avoid' and 'Drug-age Precaution' DUR Alerts by Severity Level and its Application. Yakhak Hoeji 2015;59:278-83. 

  20. Yi M-H, Chung W, Cho E, Kim R, Lee S. Factors associated with changes in pharmaceutical expenditures of outpatient care in clinic setting: Focusing on the incentive scheme to reduce total prescribed drug expenditure and the drug utilization review system. Health Policy and Management 2012;22:561-78. 

  21. Kim SO and Park S. Evaluation of Medication Duplication Management Program for Medicaid patients in South Korea. The Korean Journal of Health Economics and Policy 2014;20:01-19. 

  22. Kim D-S, Park J, Jeon H-R, Park C, Kang HA. The Effect of Korean Prospective Drug Utilization Review Program on the Prescription Rate of Drug-Drug Interactions. Health Policy and Management 2014;24:120-7. 

  23. Shin JY, Kim MH, Shin SM, Lee SH, Park BJ. Dramatic decrease in fluoroquinolones in the pediatric population in Korea. Pharmacoepidemiol Drug Saf 2014;23:1320-4. 

    상세보기

  24. Shin JY, Lee SH, Shin SM, Shin HN, Park BJ. Regulatory action and moderate decrease in methylphenidate use among ADHD diagnosed patients aged five and under in Korea. Regul Toxicol Pharmacol 2015;72:244-8. 

    상세보기

  25. Yang JH, Kim M, Park YT, Lee EK, Jung CY, Kim S. The effect of the introduction of a nationwide DUR system where local DUR systems are operating--The Korean experience. Int J Med Inform 2015;84:912-9. 

  26. Song I, Choi SH, Shin JY. Trends in prescription of pregnancy-contraindicated drugs in Korea, 2007-2011. Regul Toxicol Pharmacol 2016;75:35-45. 

    상세보기

  27. Song I, Shin HN, Shin JY. Decrease in use of contraindicated drugs with automated alerts in children. Pediatr Int 2017;59:720-6. 

  28. Song SY, Shin JH, Hyeon SY, et al. Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015. PLoS ONE 2017; 12 DOI 10.1371/journal.pone.0176420. 

    상세보기 crossref

  29. Armstrong PW and Mant MJ. Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. Eur Heart J 1995;16:75-80. 

    상세보기

  30. Bryant AD, Fletcher GS, Payne TH. Drug interaction alert override rates in the Meaningful Use era: no evidence of progress. Appl Clin Inform 2014;5:802-13. 

    상세보기

  31. Allen LaPointe NM, Chen AY, Roe MT, et al. Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. Am J Cardiol 2009;104:1324-1329 DOI 10.1016/j.amjcard.2009.06.054. 

    상세보기 crossref

  32. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124:155-63. 

    상세보기

  33. Soumerai SB and Lipton HL. Computer-based drug-utilization review--risk, benefit, or boondoggle? NEJM 1995;332:1641-5 DOI 10.1056/nejm199506153322411. 

    상세보기 crossref

  34. Kim JY, Kim SJ, Nam CM, Moon KT, Park EC. Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea. Eur J Public Health 2018;28:209-14 DOI 10.1093/eurpub/ckx168. 

    상세보기 crossref

  35. Mossialos E, Mrazek M, Walley T. Regulating Pharmaceuticals In Europe: Striving for Efficiency, Equity and Quality. Berkshire: McGraw-Hill Education (UK), 2004;1-2. 

  36. Maynard A and Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff (Millwood) 2003;22:31. 

저자의 다른 논문 :

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로